We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+3.22%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$179M
AUM Growth
-$30.2M
Cap. Flow
+$1.11M
Cap. Flow %
0.62%
Top 10 Hldgs %
63.13%
Holding
65
New
9
Increased
21
Reduced
4
Closed
24

Top Buys

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$7.06M
2
VCYT icon
Veracyte
VCYT
+$6.04M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$4.72M
4
IMMU
Immunomedics Inc
IMMU
+$3.51M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.2M

Top Sells

Rank Stock Value
1
OLED icon
Universal Display
OLED
+$10.6M
2
INCY icon
Incyte
INCY
+$4.78M
3
EXEL icon
Exelixis
EXEL
+$3.75M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.17M
5
TVTX icon
Travere Therapeutics
TVTX
+$2.58M

Sector Composition

Rank Sector Weight
1 Healthcare 79.17%
2 Miscellaneous 18.71%
3 Technology 2.12%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CUTR
51
DELISTED
Cutera, Inc.
CUTR
– –
-113,807
Closed -$1.46M
NBSE
52
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-25
Closed -$61K
CLVS
53
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-30,000
Closed -$1.05M
KIN
54
DELISTED
Kindred Biosciences, Inc.
KIN
– –
-50,000
Closed -$170K
CORV
55
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
– –
-82,552
Closed -$669K
QLTI
56
DELISTED
QLT Inc
QLTI
– –
-301,160
Closed -$801K
PTX
57
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-43,430
Closed -$1.28M
SGNT
58
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-144,667
Closed -$2.3M
HTWR
59
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-34,587
Closed -$1.74M
BEAT
60
DELISTED
BioTelemetry, Inc.
BEAT
– –
-150,322
Closed -$1.76M
LJPC
61
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-82,920
Closed -$2.24M
1 2
3

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q1 2016 Portfolio in Review

As of Q1 2016, Acuta Capital Partners held 65 positions worth $179M, down 14% from $209M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Acuta Capital Partners's Q1 2016 filing shows 9 new, 21 increased, 4 reduced and 24 closed positions. Its largest new stake was Akebia Therapeutics: 386,308 shares worth $3.48M. The largest sale was Universal Display, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 73% a quarter earlier, followed by Miscellaneous and Technology.

  • Acuta Capital Partners's largest Q1 2016 buy was Akebia Therapeutics: 386,308 shares worth $3.48M.
  • Acuta Capital Partners added most to Amicus Therapeutics in Q1 2016, an estimated $7.06M increase.
  • Acuta Capital Partners's biggest Q1 2016 reduction was Universal Display, cutting an estimated $10.6M.
  • Acuta Capital Partners fully exited Incyte in Q1 2016, selling an estimated $4.78M.
  • Acuta Capital Partners's ten largest holdings make up 63% of its $179M portfolio in Q1 2016.
  • Acuta Capital Partners opened 9 new positions and closed 24 in Q1 2016.
  • Acuta Capital Partners's portfolio value fell 14% quarter-over-quarter to $179M.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.